PepT1-mediated uptake of tripeptides has been shown to reduce nuclear factor κB (NF-κB) and mitogen-activated protein (MAP) kinase inflammatory signaling pathways and proinflammatory cytokine secretion and reduced the incidence of colitis in mice, raising the use of anti-inflammatory oligopeptides as attractive therapeutic strategy against IBD (27–30). Here, SLC15A1 is linked to inflammatory bowel disease.